tiprankstipranks
Revolution Medicines, Inc. (RVMD)
NASDAQ:RVMD
US Market
RVMD
Revolution Medicines
RESEARCH TOOLSreports
Want to see RVMD full AI Analyst Report?

Revolution Medicines (RVMD) Stock Forecast & Price Target

804 Followers
See the Price Targets and Ratings of:

RVMD Analyst Ratings

Strong Buy
21Ratings
Strong Buy
20 Buy
1 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Revolution
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$183.65
▲(23.56% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $183.65 with a high forecast of $263.00 and a low forecast of $140.00. The average price target represents a 23.56% change from the last price of $148.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","264":"$264","92.25":"$92.3","149.5":"$149.5","206.75":"$206.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$263.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183.64705882352942,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$183.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,92.25,149.5,206.75,264],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.68,171.32,178.96,186.6,194.24,201.88,209.52,217.16,224.8,232.44,240.07999999999998,247.72,255.36,{"y":263,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.68,165.21592760180997,166.75185520361993,168.28778280542988,169.82371040723982,171.35963800904977,172.89556561085973,174.4314932126697,175.96742081447965,177.5033484162896,179.03927601809954,180.5752036199095,182.11113122171946,{"y":183.64705882352942,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.68,161.85846153846154,160.03692307692307,158.2153846153846,156.39384615384617,154.5723076923077,152.75076923076924,150.92923076923077,149.1076923076923,147.28615384615384,145.4646153846154,143.64307692307693,141.82153846153847,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.48,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$263.00Average Price Target$183.65Lowest Price Target$140.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$169→$195
Buy
31.20%
Upside
Reiterated
06/02/26
Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightRevolution Medicines price target raised to $195 from $169 at H.C. Wainwright
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$165
Buy
11.01%
Upside
Assigned
06/02/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Crescent Biopharma (NASDAQ: CBIO) and Erasca (NASDAQ: ERAS)
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
Bernstein Analyst forecast on RVMD
Unknown Analyst
Bernstein
Not Ranked
Bernstein
―
Hold
―
Reiterated
06/01/26
Bernstein Reaffirms Their Hold Rating on Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$183
Buy
23.12%
Upside
Reiterated
06/01/26
Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target
Guggenheim Analyst forecast on RVMD
Michael Schmidt
Guggenheim
Guggenheim
$205
Buy
37.93%
Upside
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$165→$195
Buy
31.20%
Upside
Assigned
06/01/26
Oppenheimer Remains a Buy on Revolution Medicines (RVMD)
TD Cowen Analyst forecast on RVMD
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IN8bio (NASDAQ: INAB) and PolyPid (NASDAQ: PYPD)
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$263
Buy
76.95%
Upside
Reiterated
06/01/26
Charles Zhu Reiterates Buy on RVMD, Maintains $263 Price Target on Strong Darax Data and Regulatory Progress
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$200→$167
Buy
12.36%
Upside
Assigned
06/01/26
Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD)
Truist Financial Analyst forecast on RVMD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Veeva Systems (NYSE: VEEV)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
44.65%
Upside
Reiterated
06/01/26
Stifel Nicolaus Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$165
Buy
11.01%
Upside
Reiterated
06/01/26
Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Bank of America Securities Analyst forecast on RVMD
Alec Stranahan
Bank of America Securities
Bank of America Securities
$185
Buy
24.47%
Upside
Reiterated
06/01/26
Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Revolution Medicines (NASDAQ: RVMD) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
UBS Analyst forecast on RVMD
Michael Yee
UBS
UBS
$145→$175
Buy
17.74%
Upside
Assigned
05/31/26
Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$169→$195
Buy
31.20%
Upside
Reiterated
06/02/26
Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightRevolution Medicines price target raised to $195 from $169 at H.C. Wainwright
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$165
Buy
11.01%
Upside
Assigned
06/02/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Crescent Biopharma (NASDAQ: CBIO) and Erasca (NASDAQ: ERAS)
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
Bernstein Analyst forecast on RVMD
Unknown Analyst
Bernstein
Not Ranked
Bernstein
―
Hold
―
Reiterated
06/01/26
Bernstein Reaffirms Their Hold Rating on Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$183
Buy
23.12%
Upside
Reiterated
06/01/26
Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target
Guggenheim Analyst forecast on RVMD
Michael Schmidt
Guggenheim
Guggenheim
$205
Buy
37.93%
Upside
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$165→$195
Buy
31.20%
Upside
Assigned
06/01/26
Oppenheimer Remains a Buy on Revolution Medicines (RVMD)
TD Cowen Analyst forecast on RVMD
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IN8bio (NASDAQ: INAB) and PolyPid (NASDAQ: PYPD)
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$263
Buy
76.95%
Upside
Reiterated
06/01/26
Charles Zhu Reiterates Buy on RVMD, Maintains $263 Price Target on Strong Darax Data and Regulatory Progress
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$200→$167
Buy
12.36%
Upside
Assigned
06/01/26
Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD)
Truist Financial Analyst forecast on RVMD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Veeva Systems (NYSE: VEEV)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
44.65%
Upside
Reiterated
06/01/26
Stifel Nicolaus Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$165
Buy
11.01%
Upside
Reiterated
06/01/26
Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Bank of America Securities Analyst forecast on RVMD
Alec Stranahan
Bank of America Securities
Bank of America Securities
$185
Buy
24.47%
Upside
Reiterated
06/01/26
Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Revolution Medicines (NASDAQ: RVMD) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
UBS Analyst forecast on RVMD
Michael Yee
UBS
UBS
$145→$175
Buy
17.74%
Upside
Assigned
05/31/26
Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months
Joseph CatanzaroMizuho Securities
Success Rate
10/12 ratings generated profit
83%
Average Return
+26.02%
Copying Joseph Catanzaro's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +26.02% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
15/15 ratings generated profit
100%
Average Return
+93.25%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +93.25% per trade.
2 Years
Peter LawsonBarclays
Success Rate
13/13 ratings generated profit
100%
Average Return
+265.26%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +265.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
5
7
7
10
9
Buy
45
47
53
52
55
Hold
0
0
0
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
50
54
60
64
67
In the current month, RVMD has received 64 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 183.65.
Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$1.96 with a range of -$2.19 to -$0.85. The previous quarter’s EPS was -$2.29. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s earnings estimate for RVMD is -$1.96 with a range of -$2.19 to -$0.85. The previous quarter’s EPS was -$2.29. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $18.06M with a range of $0.00 to $250.00M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s sales forecast for RVMD is $18.06M with a range of $0.00 to $250.00M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines, Inc.’s 12-month average price target is 183.65.
    What is RVMD’s upside potential, based on the analysts’ average price target?
    Revolution Medicines, Inc. has 23.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RVMD a Buy, Sell or Hold?
          Revolution Medicines, Inc. has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Revolution Medicines, Inc.’s price target?
            The average price target for Revolution Medicines, Inc. is 183.65. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $263.00 ,the lowest forecast is $140.00. The average price target represents 23.56% Increase from the current price of $148.63.
              What do analysts say about Revolution Medicines, Inc.?
              Revolution Medicines, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of RVMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.